China SFDA Seeks Public Comment On Change To Proposed Definition Of “New” Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency’s draft drug registration rules propose to eliminate China’s fast track approval process for certain types of drugs, including AIDS and oncologics.
You may also be interested in...
Simcere Seeks Oncology Acquisitions, Ex-China Licensing Partners For Endu
Simcere Pharmaceutical Group plans to be one of the last China-based pharmaceutical firms standing after a predicted major consolidation could shrink that industry to as few as 1,000 companies in the next several years
Simcere Seeks Oncology Acquisitions, Ex-China Licensing Partners For Endu
Consolidation could shrink China’s pharmaceutical industry from 4,000 firms today to as few as 1,000 in future, Simcere CEO tells investors at Goldman Sachs conference.
Simcere Seeks Oncology Acquisitions, Ex-China Licensing Partners For Endu
Consolidation could shrink China’s pharmaceutical industry from 4,000 firms today to as few as 1,000 in future, Simcere CEO tells investors at Goldman Sachs conference.